MDS this week announced the formation of a committee to review alternatives to boost shareholder value.
The committee is composed of independent directors with no ties to MDS’ management. The members are William Anderson; Robert Luba; James MacDonald; and Gregory Spivy. MacDonald will act as chair.
Goldman Sachs and RBC Capital Markets are acting as financial advisors to the company and the board of directors. No timetable has been set for the completion of the review.
The move comes after MDS laid off 210 employees in its Analytical Technologies business, which develops and manufactures mass specs, and its MDS Pharma unit during the summer.
In December, the company reported a 4-percent decline in revenues to $322 million for its fiscal fourth quarter. MDS Analytical Technologies had a drop in revenue to $99 million from $108 million. The firm said then that the division continues to be impacted by soft demand for high-end instruments.
Monette Greenway has joined Strategic Diagnostics as vice president of marketing and sales, effective Jan. 28, the company announced this week. Also, Robert Laffer joined the company as sales manager for life sciences, effective Jan. 15.
Greenway fills the role left vacant when Fran DiNuzzo was appointed CEO in November. She had been president of integrative technologies at Thermo Fisher Scientific. Before that, she held vice president and general manager roles at Invitrogen.
Laffer was northeast regional sales manager for Panomics before joining SDI. Before that, he was global account executive for the BioPharma division of PerkinElmer.